首页> 外文期刊>Brain, Behavior, and Immunity >Spinal versus brain microglial and macrophage activation traits determine the differential neuroinflammatory responses and analgesic effect of minocycline in chronic neuropathic pain
【24h】

Spinal versus brain microglial and macrophage activation traits determine the differential neuroinflammatory responses and analgesic effect of minocycline in chronic neuropathic pain

机译:脊髓与脑小胶质细胞和巨噬细胞的活化特性决定了米诺环素在慢性神经性疼痛中的差异性神经炎症反应和镇痛作用

获取原文
获取原文并翻译 | 示例
           

摘要

Substantial evidence indicates involvement of microglia/macrophages in chronic neuropathic pain. However, the temporal-spatial features of microglial/macrophage activation and their pain-bound roles remain elusive. Here, we evaluated microglia/macrophages and the subtypes in the lumbar spinal cord (SC) and prefrontal cortex (PFC), and analgesic-anxiolytic effect of minocycline at different stages following spared nerve injury (SNI) in rats. While SNI enhanced the number of spinal microglia/macrophages since post-operative day (POD)3, pro-inflammatory MHCII+ spinal microglia/macrophages were unexpectedly less abundant in SNI rats than shams on POD21. By contrast, less abundant anti-inflammatory CD172a (SIRP alpha)(+) microglia/macrophages were found in the PFC of SNI rats. Interestingly in naive rats, microglial/macrophage expression of CD11b/c, MHCII and MHCII+/CD172a(+) ratio were higher in the SC than the cortex. Consistently, multiple immune genes involved in anti-inflammation, phagocytosis, complement activation and M2 microglial/macrophage polarization were upregulated in the spinal dorsal horn and dorsal root ganglia but downregulated in the PFC of SNI rats. Furthermore, daily intrathecal minocycline treatment starting from PODO for two weeks alleviated mechanical allodynia most robustly before POD3 and attenuated anxiety on POD9. Although minocycline dampened spinal MHCII microglia/macrophages until POD13, it failed to do so on cortical microglia/macrophages, indicating that dampening only spinal inflammation may not be enough to alleviate centralized pain at the chronic stage. Taken together, our data provide the first evidence that basal microglial/macrophage traits underlie differential region-specific responses to SNI and minocycline treatment, and suggest that drug treatment efficiently targeting not only spinal but also brain inflammation may be more effective in treating chronic neuropathic pain. (C) 2016 Elsevier Inc. All rights reserved.
机译:大量证据表明小胶质细胞/巨噬细胞参与了慢性神经性疼痛。然而,小胶质细胞/巨噬细胞激活的时空特征及其痛苦的作用仍然难以捉摸。在这里,我们评估了小胶质细胞/巨噬细胞和腰脊髓(SC)和额叶前皮层(PFC)中的亚型,以及米诺环素在大鼠神经损伤(SNI)后不同阶段的镇痛和抗焦虑作用。自手术后(POD)3以来SNI增强了脊髓小胶质细胞/巨噬细胞的数量,但SNI大鼠中促炎性MHCII +脊髓小胶质细胞/巨噬细胞的丰富度出乎意料地比POD21上的毛囊少。相比之下,在SNI大鼠的PFC中发现了数量较少的抗炎CD172a(SIRP alpha)(+)小胶质细胞/巨噬细胞。有趣的是,在幼稚的大鼠中,SC中的CD11b / c,MHCII和MHCII + / CD172a(+)比值的小胶质细胞/巨噬细胞表达高于皮质。一致地,参与抗炎,吞噬作用,补体激活和M2小胶质细胞/巨噬细胞极化的多种免疫基因在脊髓背角和背根神经节中上调,但在SNI大鼠的PFC中下调。此外,从PODO开始连续两周每天进行鞘内注射美诺环素治疗,在POD3之前最有效地减轻了机械性异常性疼痛,并减轻了POD9上的焦虑。尽管米诺环素可以抑制脊髓MHCII小胶质细胞/巨噬细胞直至POD13,但它对皮层小胶质细胞/巨噬细胞没有作用,这表明仅抑制脊柱炎症可能不足以缓解慢性阶段的中央性疼痛。综上所述,我们的数据提供了第一个证据,即基底微胶质细胞/巨噬细胞性状是针对SNI和米诺环素治疗的不同区域特异性反应的基础,并表明有效针对脊髓和脑部炎症的药物治疗可能更有效地治疗慢性神经性疼痛。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号